Memantine effect on treatment of drug resistant obsessive obsessive compulsive disorder

Not Applicable

Conditions: obsessive compulsive disorder.
Obsessive-compulsive disorder

Registration Number: IRCT2015110324853N1

Lead Sponsor: Deputy of research and technology developement

Brief Summary: Introduction: Despite proven efficacy ofserotonin reuptake inhibitors (SRIs) in the treatment of obsessive–compulsive disorder (OCD), refractoryOCD is still a therapeutic challenge. There is a large body of evidence on the clinical benefits of augmentation therapy with glutamate-modulating agents such as memantine in reducing OCDsymptoms. The aim of the present study was to assess the efficacy ofmemantine augmentation in SRI-refractory OCD patients. Materials and methods: A double-blind, randomized, placebo controlled trial was conducted onSRI-refractory OCD patients who had failed at least 3 SRI trials. 32 patients, stable on an existing SRI for a minimum of 3 months were recruited and received either 20mg/daymemantine or placebo augmentation for 12 weeks. Patients were visited at baseline and then every four weeks and results were measured using the Yale-Brown Obsessive-Compulsive Scale (Y-BOCS). Results: Y-BOCS total scores weresignificantly reduced in the memantine group at the end of weeks 8 and 12, while no improvement was observed in the placebo group throughout the trial. A reduction of 40.9% in the mean Y-BOCS total score by week 12 in the memantine group resulted in 100% of patients achieving treatment response.The findings showed that a time to effect of 8 weeks was necessary to observe significant improvement in OCD symptoms, while treatment response was only seen after 12 weeks of memantine augmentation. Conclusions: High dose memantinecan be an effective and well-tolerated augmentation in severe OCD patientsrefractory toSRI monotherapy. Keywords: Obsessive-compulsive disorder, Serotonin reuptake inhibitors,N-methyl-D-aspartate antagonist,glutamate receptor,memantine, treatment refractory.

Detailed Description: Not available

Recruitment & Eligibility

Status: Complete

Sex: All

Target Recruitment: 32

Inclusion Criteria

patients with known obsessive compulsive disorder by DSM-V criteria; no other mental disorder; no other systemic disorder such as diabetes,hypertension,hyper and hypo thyroidism ;no alcohol intake and not a drug user; between 18 to 40 years old; the patient should be treated for at least 3 months with an antidepressant at highest dose and have a score of 21 or more in Yale-Brown Obsessive Compulsive Scale test.
exclusion criteria:Pregnancy and nursing; Patients with a history of memantine use; Patients who do not sign the consent form.

Exclusion Criteria

Not provided